Today: 7 February 2026
Subscribe
Browse Category

TSX:7762 News 23 August 2025

Rugged Watch Showdown 2025: Citizen Promaster Tough vs Alpina AlpinerX Pro GPS vs Seiko Prospex Fieldmaster

Rugged Watch Showdown 2025: Citizen Promaster Tough vs Alpina AlpinerX Pro GPS vs Seiko Prospex Fieldmaster

Citizen Promaster Tough uses a one-piece monocoque case with Duratect hardening, making the case five times harder than standard steel, and is offered with a 5-year warranty. The 2023 Ray Mears edition in Super Titanium (BN0118/BN0241) measures 41mm x ~12mm and weighs about 50g. The Promaster Tough runs on Citizen Eco-Drive Caliber E168, a solar quartz movement that yields up to six months of run time in darkness on a full charge. It is rated to 200m water resistance with a screw-down crown and sapphire crystal, and it has no smart sensors or digital displays. AlpinerX Pro GPS Alive uses
23 August 2025

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop